contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-oyj-managers-transactions-henri-huttunen-8

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Antti has updated the new company report based on the latest information   Herantis Pharma released additional details regarding the next clinical trial for the HER-096 drug candidate for Parkinson’s disease. The Phase 2a trial, aiming for preliminary proof of efficacy, is likely to begin next year and last approximately two years. The completion of results will take longer than our previous forecast, so we are shifting our estimate for the drug’s launch to 2034 (previously 2033). The postponement of cash flows lowers the share value in the DCF calculation, so we are adjusting our target price to 2.2 euros (prev. 2.4 €). Our assessment of the risk-reward ratio remains unsatisfactory, so we are lowering our recommendation to Reduce (prev. Accumulate).                    Inderes              Herantis: Tehotutkimuksen yksityiskohtiin selvyyttä - Inderes    Tutkimus tuottaa korkealaatuista dataa Parkinsonin taudin lääkeaihion turvallisuudesta ja alustavasti sen tehosta.

Herantis Pharma’s Chief Scientific Officer Henri Huttunen was interviewed by Antti    Topics: (00:00) Introduction  (00:09) Phase 2 study  (00:55) Endpoint  (02:05) Digital tools  (03:10) Secondary endpoints  (03:50) 100-patient study  (06:23) Study timeline  (07:29) Pros and cons of the study  (09:18) Role of the FDA  (11:04) Post-study period  (12:25) Phase 3 / Phase 2b  (13:29) Financing situation

Inderes              Herantis raportoi positiivisesta FDA-palautteesta ja viimeistelee...    Herantis Pharma Oyj – Lehdistötiedote 2.6.2026 klo 12.20Herantis raportoi positiivisesta FDA-palautteesta ja viimeistelee HER-096:n vaiheen 2a tutkimusasetelmanFDA piti suunniteltua HER-096:...                             Positive FDA news was released a moment ago

The information provided regarding the Phase 2 study has been quite general so far. In the interview linked by Sijoittaja-alokas above, Vuolanto mentions that they aim to provide more detailed information about the P2 study design “within the next four weeks,” which likely means going deeper into concrete scientific, clinical, and practical details. One could certainly hope for news regarding the financing arrangements as well, but in my opinion, that is fairly unlikely. Edit: And naturally, there will likely be more detailed information about the Invidi collaboration, and the audience will have the opportunity to ask questions.

The company has already reported on both topics, although they could certainly provide endless additional details. Since the finance team is also present, I wonder how it relates to those topics. A press release regarding financing negotiations? It would be strange at this point and perhaps a bad sign for that side of things…

June 2nd: Phase 2 preparation status update to be held                   Inderes              Webcast: Vaiheen 2 valmistelujen tilannekatsaus - Inderes    Herantis Pharma Oyj – Lehdistötiedote 28.5.2026 klo 14.30Webcast: Vaiheen 2 valmistelujen tilannekatsausEspoo, Suomi, 28 Toukokuu 2026: Herantis Pharma Oyj (“Herantis”), kliinisen vaiheen bioteknologi...

Herantis CEO Antti Vuolanto spoke about the company as an investment opportunity at the Investor Day

Herantis Pharma

Herantis Pharma PlcCompany release 13 May 2026 at 17:30 EESTHerantis Pharma Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName...

Herantis Pharma PlcCompany release 13 May 2026 at 17:30 EESTHerantis Pharma Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Henri HuttunenPosition: Other senior managerIssuer: Herantis Pharma OyjLEI: 743700W4CQVYAT3WKK38Notification type: INITIAL NOTIFICATIONReference number: 156787/5/4____________________________________________Transaction date: 2026-05-13Outside a trading venueInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTName of the instrument: 2026 option rights in Herantis Pharma PlcNature of transaction: ACCEPTANCE OF A STOCK OPTIONTransaction details(1): Volume: 100200 Unit price: 0 EURAggregated transactions (1):Volume: 100200 Volume weighted average price: 0 EUR____________________________________________For more information, please contact:Tone Kvåle, CFOTel: +47 915 19576Email: <a href="mailto:ir@herantis.com">ir@herantis.com</a>Certified Advisor: UB Corporate Finance Oy, Finland: +358 9 25 380&nbsp;225<a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>Company website: www.herantis.com

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen